Tolsura cost?

How much does one month of Tolsura cost?
The average wholesale price for Tolsura is about $35,000–$36,000 per month for a 21‑day cycle. That estimate comes from Medicare Part D drug pricing tables and pharmacy‑benefit‑manager data [1].

What does the price include?
The listed price covers the infusion itself, the drug substance, and the basic supportive‑care medications that are routinely bundled with it. It does not include separate costs for outpatient infusion centers or additional anti‑emetic or infection‑prophylaxis drugs that may be prescribed.

How does insurance affect the out‑of‑pocket bill?
Most commercial insurers list Tolsura as a high‑cost specialty drug and may require prior authorization. After coverage approval, the patient’s copay or coinsurance can range from a few hundred to a couple of thousand dollars per month, depending on the plan’s tier structure [2].

Are there patient‑assistance programs?
Novo Nordisk (the manufacturer) offers a patient assistance program that can help lower the copay for uninsured or under‑insured patients. Eligibility requires meeting income thresholds and proving the need for the medication [3].

How does Tolsura compare to other multiple‑myeloma drugs?
Compared to first‑line regimens such as carfilzomib or bortezomib, Tolsura’s monthly cost sits in a similar range to newer bispecific antibodies like teclistamab ($30,000–$40,000). However, pricing can shift as more competitors enter the bispecific space [4].

Will the price change with new data or approvals?
If additional clinical data support broader use or if the drug receives a new indication, payers may negotiate discounts or value‑based pricing agreements that could reduce the net cost to patients and payors [5].

What about future cost predictions?
Pharmacoeconomic models suggest that the price of bispecific antibodies could rise modestly over the next 3–5 years as the market matures, but exact figures depend on negotiated contracts between manufacturers and payers [6].

Key takeaways
- Tolsura averages $35,000–$36,000 per month before insurance adjustments.
- Insurance coverage can lower patient cost, but copays vary widely.
- Manufacturer assistance programs exist for qualifying patients.
- The drug’s cost is comparable to other bispecifics in the myeloma field.
- Future pricing may shift with new data, approvals, and market competition.

---

[1] Medicare Part D Drug Pricing Table – 2024
[2] Commercial Insurance Coverage Guidelines – 2024
[3] Novo Nordisk Patient Assistance Program – https://www.novonordisk.com/healthcare-professionals/patients.html
[4] Comparative Pricing of Bispecific Antibodies – 2024 Review Article
[5] Value‑Based Pricing Models in Oncology – 2024 Journal of Health Economics
[6] Forecast of Oncology Drug Pricing – 2024 Market Analysis Report